Gilead Sciences (MIL:1GILD) Capital Expenditure : €-344.41 Mil (TTM As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Gilead Sciences Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Gilead Sciences's cash flow for capital expenditures for the three months ended in Dec. 2024 was €0 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2024 was €-344.41 Mil.

Gilead Sciences Capital Expenditure Historical Data

The historical data trend for Gilead Sciences's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Capital Expenditure Chart

Gilead Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Capital Expenditure

Get a 7-Day Free Trial

-534.30

-512.42

-687.23

-536.45

Gilead Sciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Capital Expenditure	Get a 7-Day Free Trial															-197.16	-96.60	-120.77	-127.04	-

Gilead Sciences Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-344.41 Mil.

Gilead Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (MIL:1GILD) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Peru GILD:Mexico GISd:UK 0QYQ:UK GIS:Germany GILD:Chile GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences Headlines

No Headlines